Back to top
more

Kindred Biosciences, Inc. (KIN)

(Delayed Data from NSDQ)

$9.16 USD

9.16
138,522

+0.33 (3.74%)

Updated May 3, 2019 04:00 PM ET

After-Market: $9.16 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[KIN]

Reports for Purchase

Showing records 1 - 20 ( 63 total )

Industry: Medical - Biomedical and Genetics

Record: 1

08/24/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for KIN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

06/17/2021

Company Report

Pages: 6

KindredBio Announces Buyout Agreement; Downgrade to Neutral with $9.25 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

05/12/2021

Company Report

Pages: 6

Continued Progress in Parvovirus and Dermatitis Programs; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

03/18/2021

Company Report

Pages: 8

Expected Approval of KIND-030 by YE21; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

12/23/2020

Daily Note

Pages: 3

Pipeline Development on Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

12/15/2020

Daily Note

Pages: 4

Elanco Partnership Provides Further Validation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

11/10/2020

Company Report

Pages: 8

Second KIND-030 Pivotal Readout by Year End; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

09/21/2020

Daily Note

Pages: 3

Positive Prophylactic Pivotal Efficacy Data for KIND-030; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

08/06/2020

Company Report

Pages: 6

Pipeline Progress on Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

06/10/2020

Company Report

Pages: 6

Streamline Operations to Cater to Strategic Shift; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

05/08/2020

Company Report

Pages: 6

Multiple Clinical Catalysts in View; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

03/17/2020

Company Report

Pages: 7

Committing to a Lower Risk Business Model; Adjust PT to $9.00; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

01/09/2020

Daily Note

Pages: 3

Technology Development to Bolster Canine Biologics Pipeline; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 14

12/17/2019

Daily Note

Pages: 3

Canine AD Development Franchise Strengthened; Two Approvals Pocketed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 15

11/13/2019

Company Report

Pages: 7

Two Approvals Expected by YE; Adjust PT to $16.00; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 16

09/12/2019

Daily Note

Pages: 3

NCI Contract Validates cGMP Biologicals Manufacturing Expertise; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 17

08/02/2019

Company Report

Pages: 7

Mirataz Sales Back on Track; Catalyst-rich 2H19; Reiterate Buy; Adjust PT to $17.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 18

07/30/2019

Daily Note

Pages: 4

Positive Top-Line Results From KIND-016 Pilot Study; Pivotal Study to Start in 2H19; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 19

07/10/2019

Industry Report

Pages: 22

Online gaming sector - Diversification and scale for online success

Provider: Edison Investment Research Limited

Price: .00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 20

05/10/2019

Company Report

Pages: 7

Tepid Mirataz Sales; But Too Early to Be Disappointed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party